{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:03Z","timestamp":1791389883152,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":140,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03000257"],"award-info":[{"award-number":["NCT03000257"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100405","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T02:25:47Z","timestamp":1621909547000},"page":"100405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"Emiliano","family":"Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda de","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomo","family":"Alanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriina","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Afar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Englert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Komarnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurvasena","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Vosganian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100405_bib0001","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0002","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0003","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0004","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2021.100405_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0007","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0008","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0009","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100405_bib0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100405_bib0011","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4161\/mabs.26436","article-title":"Effects of altered Fc\u03b3R binding on antibody pharmacokinetics in cynomolgus monkeys","volume":"5","author":"Leabman","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.ctarc.2021.100405_bib0012","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1093\/annonc\/mdy279.425","article-title":"Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: preliminary phase 1 results from study M15-892","volume":"29","author":"Powderly","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0013","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/annonc\/mdz253.113","article-title":"Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma","volume":"30","author":"Italiano","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0014","first-page":"310","article-title":"Identification of candidate responders for anti-PD-L1\/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer","volume":"8","author":"Saito","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ctarc.2021.100405_bib0017","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100405_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0019","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1158\/1538-7445.AM2019-3950","article-title":"Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous Dll3 expression","volume":"79","author":"Vitorno","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100405_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8516","article-title":"Ph1\/2 study of Rova-T in combination with nivolumab (Nivo) \u00b1 ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC","volume":"37","author":"Malhotra","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0021","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/annonc\/mdz264.012","article-title":"Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer","volume":"30","author":"Calvo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0022","first-page":"P690","article-title":"Pharmacokinetics (PK) and dosing regimen selection of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: preliminary phase 1 results from study M15-891","volume":"6","author":"Parikh","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2021.100405_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers11030305","article-title":"Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features","volume":"11","author":"Porcu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2021.100405_bib0024","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2021.100405_bib0027","doi-asserted-by":"crossref","unstructured":"Chung H.C., Lopez-Martin J.A., Kao S.C.H., et\u00a0al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J. Clin. Oncol.. 2018;36: abstract 8506. doi:10.1200\/JCO.2018.36.15_suppl.8506.","DOI":"10.1200\/JCO.2018.36.15_suppl.8506"},{"key":"10.1016\/j.ctarc.2021.100405_bib0028","doi-asserted-by":"crossref","unstructured":"George J., Saito M., Tsuta K., et\u00a0al. Genomic amplification of CD274 (PD-L1) in small-cell lung cancer. Clin. Cancer Res.. 2017;23:1220\u20131226. doi:10.1158\/1078-0432.CCR-16-1069.","DOI":"10.1158\/1078-0432.CCR-16-1069"},{"key":"10.1016\/j.ctarc.2021.100405_bib0029","doi-asserted-by":"crossref","unstructured":"Gadgeel S.M., Pennell N.A., Fidler M.J., et\u00a0al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J. Thorac. Oncol.. 2018;13:1393\u20131399. doi:10.1016\/j.jtho.2018.05.002.","DOI":"10.1016\/j.jtho.2018.05.002"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:10:29Z","timestamp":1778893829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"alternative-id":["S2468294221001039"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100405","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100405"}}